|Last Update: 05/17/13 - 4:00 PM EDT|
|YTD Performance: 24.35%|
|Previous Close: $96.38|
|52 Week Range: $67.64 - $98.88|
|Oustanding Shares: 171,879,430|
|Market Cap: 16,565,739,463|
|Qtr (06/13)||Qtr (09/13)||FY (12/13)||FY (12/14)|
|Number of Analysts||8||8||8||8|
|Growth Rate (Year over Year)||12.28%||18.75%||16.37%||16.87%|
Shares of CERN now seen reaching $95, according to Credit Suisse. Estimates also increased, as strong system sales are driving higher margins. Neutral rating.
As medical practices are forces to upgrade their systems, this company is in a good spot.
Shares of CERN now seen reaching $88, according to Credit Suisse. Estimates also increased, as the company is carrying a lot of earnings momentum into the new year. Neutral rating.
Shares of CERN now seen reaching $54, Oppenheimer said. Estimates also raised on bookings delivering upside. Underperform rating.
Shares of CERN now seen reaching $97, Jefferies said. Estimates also raised on better than expected bookings. Buy rating.
CERN was initiated with a Buy rating, Argus said. $89 price target. Company can continue to gain market share.
Two former leading big-cap growth names are getting 200-day support.
Shares of CERN upgraded to Buy from Hold, Jefferies said. $82 price target. Better entry point.
High-multiple stocks with heavy institutional ownership can hurt your long-term financial situation.
CERN was downgraded from Overweight to Equal-weight, Morgan Stanley said. Bookings growth could slow down in the coming quarters.